NASDAQ · TEM
Healthcare · Medical - Healthcare Information Services
$70.93
Up+$1.65 (+2.38%)
Updated Oct 10, 2026, 9:10 PM
SID Score
6.7/10
Composite research score
Smart Money
60/100
Neutral
Price performance · TEM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
TEM closed at $70.93 after 21 trading sessions, up 20.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $70.20 | $72.96 | $69.20 | $70.93 | 6.27M |
| Oct 8, 2026 | $68.855 | $69.75 | $66.71 | $69.28 | 7.48M |
| Oct 7, 2026 | $70.10 | $73.09 | $68.6601 | $70.35 | 9.01M |
| Oct 6, 2026 | $84.965 | $87.99 | $71.34 | $71.98 | 16.56M |
| Oct 5, 2026 | $76.68 | $84.01 | $76.17 | $83.55 | 7.27M |
| Oct 2, 2026 | $77.36 | $80.305 | $75.8002 | $76.63 | 5.69M |
| Oct 1, 2026 | $81.98 | $82.81 | $75.92 | $76.50 | 7.18M |
| Sep 30, 2026 | $83.00 | $86.25 | $81.68 | $81.90 | 4.58M |
| Sep 29, 2026 | $85.485 | $89.09 | $81.78 | $82.58 | 6.3M |
| Sep 28, 2026 | $83.57 | $86.4399 | $82.77 | $85.08 | 6.29M |
| Sep 25, 2026 | $83.695 | $85.46 | $80.31 | $85.01 | 8.44M |
| Sep 24, 2026 | $75.69 | $82.46 | $74.81 | $82.24 | 10.82M |
| Sep 23, 2026 | $76.47 | $78.97 | $75.88 | $76.59 | 5.38M |
| Sep 22, 2026 | $77.99 | $79.00 | $75.81 | $77.19 | 6M |
| Sep 21, 2026 | $79.08 | $80.25 | $77.132 | $78.03 | 5.64M |
| Sep 18, 2026 | $81.40 | $81.83 | $75.99 | $77.84 | 9.32M |
| Sep 17, 2026 | $72.70 | $81.28 | $72.61 | $80.36 | 16.88M |
| Sep 16, 2026 | $68.79 | $71.48 | $68.4201 | $69.97 | 7.59M |
| Sep 15, 2026 | $61.905 | $68.939 | $61.88 | $68.85 | 8.25M |
| Sep 14, 2026 | $57.725 | $62.81 | $57.72 | $62.21 | 4.72M |
| Sep 11, 2026 | $59.47 | $60.38 | $58.48 | $59.01 | 3.69M |
The latest Smart Investors Daily articles mentioning TEM.
Company
Market Activity
Research & News
TEM research
Company profile and research snapshot.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 21, 2026 | Goldman Sachs | Neutral | — |
| Sep 11, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Sep 8, 2026 | Rothschild & Co | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
CHICAGO, October 01, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid.
Benzinga · Oct 1, 2026
Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $65 to $92.
Yahoo · Sep 30, 2026
Cathie Wood just dumped one of this year's biggest AI winners to load up on a stock that has barely moved, and the reasoning behind that swap reveals a lot about where she thinks the real opportunity still sits.
Yahoo · Sep 29, 2026
Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine programs, including the Company's personalized vaccine program for pediatric brain cancer patients as well as the Company's off-the-shelf precision therapy vaccines for a range of solid tumor cancers.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TEM.
